Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-escalation Study to Investigate the Safety, Tolerability, PK, PD, and Exploratory Efficacy of LP352 in Subjects With Developmental and Epileptic Encephalopathies

NCT05364021 is registered in ClinicalTrials.gov with Longboard Pharmaceuticals as lead sponsor.

NCT NCT05364021
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05364021 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-escalation Study to Investigate the Safety, Tolerability, PK, PD, and Exploratory Efficacy of LP352 in Subjects With Developmental and Epileptic Encephalopathies
Lead sponsor
Longboard Pharmaceuticals
Phase
Phase 1/2
Overall status
Completed
Start date
March 3, 2022
Completion date
November 20, 2023
Enrollment
52 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

developmental and epileptic encephalopathy, dravet syndrome, lennox gastaut syndrome